Metabolic Health: Why GLP-1s Were Never the Whole Answer

The GLP-1 boom convinced millions of people that weight management could start with a prescription — but the platforms now building around metabolic health are quietly making the opposite argument: the drug is just the door, and what happens after it is what actually separates results.

How the Category Is Reshaping Itself

Jon Michaeli, a longtime health-tech operator now at InsideTracker, makes the case from a specific vantage point: an MBA from UCLA Anderson, a background in economics from Tufts, senior roles across Medisafe, Zipline, Matternet, Vista.ai, and Sleep Number, and roughly 70 health and medtech companies he’s personally backed as an angel investor. At Medisafe he helped grow the user base from 800,000 to over 4 million, which is the kind of consumer-health scaling experience that shapes how he reads the current moment. He argues that metabolic health has outgrown its old clinical box. It used to mean a narrow set of blood markers reviewed once a year. Now it functions as a wellness category spanning nutrition, sleep, behavioral coaching, and continuous data — because, in Michaeli’s framing, metabolic health isn’t just about weight, it’s a primary driver of biological aging generally. Virtual clinics like Ro, Hims & Hers, Calibrate, and Found are the clearest evidence of the shift: GLP-1 prescriptions are the entry point, but each has built nutrition guidance, behavioral support, and coaching around the prescription rather than selling the drug on its own. Continuous glucose monitors follow the same arc — a tool that started as a clinical device for diabetics is now marketed as a general wellness instrument for tracking metabolic health day to day, a pattern Stack Archive has already covered in live-CGM products like the Ultrahuman M2.

What This Means for You

The shift from episodic to continuous care changes what “managing metabolic health” actually looks like in practice. Instead of a lab result reviewed once a year, it becomes a stream of data a person is expected to interpret and act on continuously — glucose curves, sleep quality, and recovery markers layered together instead of checked in isolation. That’s a genuinely different skill than following a doctor’s annual advice, and it’s also where most of these platforms’ business models actually live: the medication gets people in the door, but the coaching, monitoring, and behavior-change tooling around it is the recurring product. Michaeli’s own framing names the hard part directly — sustained behavior change is one of the toughest problems in consumer health, and long-term adherence, not the initial prescription or device, is what will separate the platforms that last from the ones that were riding a drug-category tailwind.

None of this requires taking a position on whether GLP-1 drugs themselves are overhyped or underrated — that debate is largely orthogonal to the point Michaeli is making. His argument is about business model, not pharmacology: platforms that treat the prescription as the entire product are building something more fragile than platforms that treat it as the entry point into a longer relationship, because patent cliffs, insurance coverage fights, and drug-specific side-effect news cycles are all risks that sit outside any single company’s control. A coaching and monitoring layer built around the drug is a hedge against exactly that volatility.

Source: Longevity.Technology

Content created with AI assistance and reviewed for accuracy.